drugset / Trial / NCT01602341

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

NCT01602341

Phase 2 Completed 86 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)

Timeline

Start
2012-08
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Crisaborole Small molecule 0.5 % Topical
Subject Crisaborole Small molecule 2 % Topical

Indications